Message to the Friedreich Ataxia Community

LX2006 Program Update – Highlights from FY & 4Q 2025

April 1, 2026

Dear Advocacy Partners and FA community members,

We are pleased to share an **update** on LX2006, our investigational gene therapy in Friedreich ataxia (FA), based on highlights from Lexeo's full-year and fourth quarter 2025 corporate update. Over the past year, we have made meaningful progress advancing LX2006 toward a pivotal clinical study, while continuing to see encouraging safety and clinical data from ongoing trials.

Highlights include:

- Updated LX2006 data were shared at the American College of Cardiology (ACC) Annual Meeting in a late-breaking oral presentation, highlighting continued positive safety and efficacy findings.
- Encouraging clinical results continue from ongoing Phase 1/2 studies of LX2006, showing improvements in heart structure and function. Participants treated with LX2006 experienced sustained reductions in left ventricular mass index (LVMI), a measure of heart thickening that is associated with serious cardiac complications in FA.
- Neurologic and functional measures also improved, including improvements in modified Friedreich Ataxia Rating Scale (mFARS) scores among participants with more than six months of follow-up, suggesting potential benefit beyond the heart.
- LX2006 has been generally well tolerated to date, with no serious (Grade 3 or higher) treatment related safety events reported.
- In February 2026, Lexeo submitted the proposed study design and statistical analysis plan for SUNRISE-FA 2, the planned open label pivotal (registrational) study of LX2006, following a Type B meeting with the FDA. The proposed study uses LVMI

as the primary endpoint and incorporates FDA feedback to help reduce potential bias.

Next steps for the LX2006 program:

- Lexeo expects to receive final FDA feedback on the SUNRISE-FA 2 protocol in the second quarter of 2026.
- The company plans to initiate the SUNRISE-FA 2 pivotal trial in the first half of 2026.

We are deeply grateful to the individuals living with FA, their families, caregivers, investigators, and advocacy partners whose dedication makes this progress possible. We will continue to share updates as we work toward bringing a potential new treatment option to the FA community.

The Lexeo Team